Literature DB >> 31506888

Determination of the cut-off prothrombin time to estimate plasma rivaroxaban overdose status.

Bohyun Kim1, Seongsoo Jang2,3,4, Yu-Jin Lee5, Nuree Park5, Young-Uk Cho6, Chan-Jeoung Park6.   

Abstract

Laboratory monitoring of rivaroxaban (RIV) is required under certain conditions. Mass spectrometry and anti-factor Xa assays are the recommended methods, which may not be readily available. Prothrombin time (PT) is the most widely used and simple coagulation assay. To set the cutoff PT and international normalized ratio (INR) to estimate RIV overdose status. RIV-spiked pooled normal plasma was used. PT test was performed using a CA-7000 coagulometer and Thromborel S reagent. The precise measurement of RIV concentration at the cut-off PT was evaluated according to the Clinical and Laboratory Standard Institute (CLSI) EP12-A2 guideline. The RIV concentration at 275 ng/mL was analyzed using 40 replicates. Receiver operating characteristic (ROC) analysis was performed to determine the cutoff value for the determination of RIV potential overdose status. An imprecision estimation of PT was conducted with 220.00 ng/mL, 247.50 ng/mL, 261.25 ng/mL, 288.75 ng/mL, 302.50 ng/mL and 330.00 ng/mL concentrations of RIV in 60 replicates. According to the ROC analysis, the cutoff clotting times and INR values to determine the overdose status of RIV were 13.45 s and 1.39. With these values, there was a 92.6% probability that plasma samples with RIV concentration ≤ 247.50 ng/mL yielded consistently negative (on-therapy dose) results, and those with ≥ 302.50 ng/mL yield consistent positive (potential overdose) results using our PT assay. PT with a reliable cutoff clotting time and INR can be used to determine the potential overdose status of RIV to facilitate the diagnosis and treatment by controlling the dose.

Entities:  

Keywords:  Anticoagulant; Cutoff; Overdose; Prothrombin time; Rivaroxaban

Mesh:

Substances:

Year:  2020        PMID: 31506888     DOI: 10.1007/s11239-019-01947-1

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  23 in total

1.  Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects.

Authors:  Dagmar Kubitza; Michael Becka; Michael Zuehlsdorf; Wolfgang Mueck
Journal:  J Clin Pharmacol       Date:  2006-05       Impact factor: 3.126

2.  The rivaroxaban-adjusted normalized ratio: use of the prothrombin time to monitor the therapeutic effect of rivaroxaban.

Authors:  B Kim; S Jang; Y J Lee; N Park; Y U Cho; C J Park
Journal:  Br J Biomed Sci       Date:  2019-06-17       Impact factor: 3.829

Review 3.  Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review.

Authors:  Bethany T Samuelson; Adam Cuker; Deborah M Siegal; Mark Crowther; David A Garcia
Journal:  Chest       Date:  2016-09-13       Impact factor: 9.410

Review 4.  Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review.

Authors:  D M Adcock; R Gosselin
Journal:  Thromb Res       Date:  2015-05-08       Impact factor: 3.944

5.  Which test to use to measure the anticoagulant effect of rivaroxaban: the prothrombin time test.

Authors:  A Tripodi
Journal:  J Thromb Haemost       Date:  2013-04       Impact factor: 5.824

6.  Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban.

Authors:  Job Harenberg; Svetlana Marx; Roland Krämer; Christina Giese; Christel Weiss
Journal:  Blood Coagul Fibrinolysis       Date:  2011-12       Impact factor: 1.276

7.  Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants.

Authors:  E M H Schmitz; K Boonen; D J A van den Heuvel; J L J van Dongen; M W M Schellings; J M A Emmen; F van der Graaf; L Brunsveld; D van de Kerkhof
Journal:  J Thromb Haemost       Date:  2014-10       Impact factor: 5.824

Review 8.  Laboratory Assessment of Direct Oral Anticoagulants.

Authors:  Jonathan Douxfils; Robert C Gosselin
Journal:  Semin Thromb Hemost       Date:  2017-03-01       Impact factor: 4.180

Review 9.  Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.

Authors:  Adam Cuker; Deborah M Siegal; Mark A Crowther; David A Garcia
Journal:  J Am Coll Cardiol       Date:  2014-09-16       Impact factor: 24.094

Review 10.  Laboratory measurement of the direct oral anticoagulants.

Authors:  Brian J Dale; Noel C Chan; John W Eikelboom
Journal:  Br J Haematol       Date:  2015-10-22       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.